Ishares Biotechnology Etf Profile
| IBB Etf | USD 124.63 1.26 1.00% |
Performance0 of 100
| Odds Of DistressLess than 38
|
IShares Biotechnology is trading at 124.63 as of the 18th of April 2024, a -1% down since the beginning of the trading day. The etf's open price was 125.89. IShares Biotechnology has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for iShares Biotechnology ETF are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. More on iShares Biotechnology ETF
Moving together with IShares Etf
| 0.7 | XBI | SPDR SP Biotech | PairCorr |
| 0.61 | IYH | iShares Healthcare ETF | PairCorr |
IShares Etf Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. IShares Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding IShares Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | George Parker |
| Thematic Ideas | (View all Themes) |
| Old Name | IBS EXCELLENCE N |
| Business Concentration | Health Care ETFs, Sector ETFs, Health, iShares (View all Sectors) |
| Issuer | iShares |
| Inception Date | 2001-02-05 |
| Benchmark | ICE Biotechnology Index (TR) (USD) |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 7.05 Billion |
| Average Trading Valume | 1.51 Million |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | JPMorgan Chase Bank, N.A. |
| Advisor | BlackRock Fund Advisors |
| Custodian | JPMorgan Chase Bank, N.A. |
| Distributor | BlackRock Investments, LLC |
| Portfolio Manager | Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason |
| Transfer Agent | JPMorgan Chase Bank, N.A. |
| Fiscal Year End | 31-Mar |
| Exchange | NASDAQ |
| Number of Constituents | 224 |
| Market Maker | Latour Trading |
| Total Expense | 0.44 |
| Management Fee | 0.44 |
| Country Name | USA |
| Returns Y T D | (6.45) |
| Name | iShares Biotechnology ETF |
| Currency Code | USD |
| Open Figi | BBG000FS8GY0 |
| In Threey Volatility | 18.59 |
| 1y Volatility | 17.55 |
| 200 Day M A | 128.7 |
| 50 Day M A | 135.59 |
| Code | IBB |
| Updated At | 17th of April 2024 |
| Currency Name | US Dollar |
iShares Biotechnology ETF [IBB] is traded in USA and was established 2001-02-05. The fund is classified under Health category within iShares family. The entity is thematically classified as Health Care ETFs. iShares Biotechnology ETF currently have 7.41 B in assets under management (AUM). , while the total return for the last 3 years was -5.8%.
Check IShares Biotechnology Probability Of Bankruptcy
Geographic Allocation (%)
Top iShares Biotechnology ETF Etf Constituents
| AMGN | Amgen Inc | Stock | Health Care |
| BIIB | Biogen Inc | Stock | Health Care |
| BMRN | Biomarin Pharmaceutical | Stock | Health Care |
| GILD | Gilead Sciences | Stock | Health Care |
| ILMN | Illumina | Stock | Health Care |
| INCY | Incyte | Stock | Health Care |
| IQV | IQVIA Holdings | Stock | Health Care |
IShares Biotechnology Target Price Odds Analysis
What are IShares Biotechnology's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of IShares Biotechnology jumping above the current price in 90 days from now is close to 99%. The iShares Biotechnology ETF probability density function shows the probability of IShares Biotechnology etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the etf has a beta coefficient of 1.2422. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, IShares Biotechnology will likely underperform. Additionally, iShares Biotechnology ETF has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of IShares Biotechnology to move above the current price in 90 days from now is close to 99 (This iShares Biotechnology ETF probability density function shows the probability of IShares Etf to fall within a particular range of prices over 90 days) .
IShares Biotechnology Top Holders
| WSACX | Wellington Shields All Cap | Mutual Fund | Large Growth |
| DEVDX | Driehaus Event Driven | Mutual Fund | Event Driven |
| HCMIX | Hcm Tactical Growth | Mutual Fund | Large Growth |
| HCMSX | Hcm Tactical Growth | Mutual Fund | Large Growth |
| HCMGX | Hcm Tactical Growth | Mutual Fund | Large Growth |
| HCMDX | Hcm Tactical Growth | Mutual Fund | Large Growth |
| QAISX | Q3 All Weather Sector | Mutual Fund | Tactical Allocation |
iShares Biotechnology ETF Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. IShares Biotechnology market risk premium is the additional return an investor will receive from holding IShares Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in IShares Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although IShares Biotechnology's alpha and beta are two of the key measurements used to evaluate IShares Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.21) | |||
| Treynor Ratio | (0.11) |
IShares Biotechnology Against Markets
Picking the right benchmark for IShares Biotechnology etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in IShares Biotechnology etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for IShares Biotechnology is critical whether you are bullish or bearish towards iShares Biotechnology ETF at a given time. Please also check how IShares Biotechnology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in IShares Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
How to buy IShares Etf?
Before investing in IShares Biotechnology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in IShares Biotechnology. To buy IShares Biotechnology etf, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of IShares Biotechnology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase IShares Biotechnology etf. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located iShares Biotechnology ETF etf in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased iShares Biotechnology ETF etf, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the etf
It's important to note that investing in stocks, such as iShares Biotechnology ETF, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in etf prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy IShares Etf please use our How to Invest in IShares Biotechnology guide.
Already Invested in iShares Biotechnology ETF?
The danger of trading iShares Biotechnology ETF is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of IShares Biotechnology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than IShares Biotechnology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile iShares Biotechnology ETF is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether iShares Biotechnology ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Biotechnology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Biotechnology Etf: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Biotechnology ETF. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the iShares Biotechnology ETF information on this page should be used as a complementary analysis to other IShares Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.